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1. Introduction
Primary glaucoma (PG) is one of the most common eye diseases which may potentially result
in bilateral blindness. Glaucoma affects 70 million people and is the second leading cause of
blindness worldwide. It is estimated that by the year 2020, this number would rise to around
79.6 million [1]. The prevalence of glaucoma varies widely across the different ethnic groups
[2-8] and is significantly higher in blacks (4.7%) as compared to the white (1.3%) population
[9]. The prevalence of both primary open angle glaucoma (POAG) and primary angle closure
glaucoma (PACG) is higher in western region of Saudi Arabia as compared to other Asian
countries [10]. To date no national study has been undertaken to determine the exact preva‐
lence of glaucoma in Saudi Arabia, though it is one of the major causes of blindness in this
country.
The glaucomas are a group of relatively common optic neuropathies in which pathological
loss of retinal ganglion cells cause progressive loss of sight and associated alteration in the
retinal nerve fiber layer and optic nerve head. Recent studies clearly suggest that abnormalities
in structure and function of retinal nerve fiber layer (RNFL) are proportional to the loss of
retinal ganglion cells in glaucoma [11]. Studies on two independent patients' populations also
confirmed a close association between RNFL thickness and several visual parameters [12]. The
retina is a light capturing tissue consisting of more than fifty different types of cells each
performing unique function that ultimately provide the visual centers in the brain the
information to achieve image formation and visual perception. Photo production require the
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retina to have a high metabolic rate, multiple and complex membrane structures [13,14]. The
photo receptor outer segments are enriched in polyunsaturated fatty acids including highly
light sensitive docosahexenoic acid [15]. Recent experimental study suggests a clear role of
fatty acids and cholesterol in optic nerve head blood flow and retinal nerve fibers structures.
Retina has a unique mechanism for lipid uptake of low density lipoproteins which provides
blood-borne lipids to all the cellular layers of retina [16,17]. Moreover, to keep its steady state
lipid composition retina has the ability to synthesize cholesterol [18]. Defects in lipid metab‐
olism in neural retina result in detrimental consequences on its structure and function.
Published data clearly suggest the crucial role of lipids and lipoproteins in the pathophsiology
of glaucoma [19]. Evidence from population and family studies supports heredity of glaucoma
to be a complex trait. It is a genetically heterogeneous disorder attributed to the effects of
individual causative mutations as well as interactions of multiple genes with a variety of
environmental factors [20].
Pseudoexfoliation syndrome (PEX) is another common and clinically significant systemic
condition and represents a complex, multifactorial, late-onset disease of worldwide signifi‐
cance with an estimated prevalence ranging from 10% to 20% of the general population [21].
It is clinically diagnosed by observation of whitish flake-like deposits of PEX material on
anterior segment structures, particularly on the anterior lens surface and the pupillary border
of the iris. Despite its worldwide distribution, there is a clear tendency for PEX syndrome to
cluster geographically and in certain racial or ethnic subgroups. For example, there is a high
prevalence of PEX syndrome in Nordic, Baltic, Mediterranean, and Arabian populations,
where it affects up to 30% of individuals over age 60. The reported mean age of PEX patients
ranges from 69 to 75years, and most epidemiological surveys demonstrate an increasing
prevalence with increasing age. There is a significantly higher frequency and severity of optic
nerve damage at the time of diagnosis, worse visual field damage, poor response to medica‐
tions, more severe clinical course, and more frequent necessity for surgical intervention.
PEX is characterized by the pathological production and accumulation of an abnormal fibrillar
extracellular material in the surface lining of the anterior and posterior chambers of the eye.
The characteristic fibrillar PEX material is composed of microfibrillar subunits surrounded by
an amorphous matrix. The material has a complex glycoprotein/proteoglycan structure
composed of a protein core surrounded by glycosaminoglycan [22,23].
The fibrillar portion has been characterized as amyloid laminin, oxytalan, and various elastic
tissue and basement membrane components [24-26]. Numerous studies showed positive
reactions of PEX material to Congo red, showing its intense fluorescence with thioflavin T and
S, and positive immunofluorescence with antiserum to amyloid, affinity for ruthenium red,
positive histochemical tests for tyrosine and tryptophan [27-30]. However some other studies
failed to demonstrate a positive reaction with Congo red in exfoliative deposits [24,27].
Hypothetically, amyloid might deposit in the vicinity of PEX material fibers because of the
affinity they both have for elastic tissues. Moreover amyloid in the skin accumulates close to
elastic fibers [31]. It has been suggested that the amyloid component normally present on
elastic fibers may serve as a ligand for the amyloid–elastic fiber association [32]. Meratoja and
Tarkkanen [30] showed amyloid positive material in sites atypical for PEX disease, such as the
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ciliary body stroma, sclera, and cornea, in eyes with PEX. Besides its presence in the eye the
PEX material is found in many other parts of the body such as the eyes, skin, heart, lungs, liver,
kidney, gall bladder, blood vessels, optic nerves, and meninges [26,33,34].
PEX is a heterogeneous group of disorders with both Mendelian and multifactorial traits. Even
within individual families, there can be large variations in the phenotypic presentation of gene
mutations. Therefore, multifactorial etiologies must be involved in PEX development. This can
include polygenic and environmental factors [35]. Some genes may act as susceptibility factors
that allow other genes or environmental influences to produce PEX. Further, familial aggre‐
gation and the increased frequency of PEX in relatives of affected subjects compared with
relatives of unaffected subjects [36,37] suggest an underlying genetic component [38]. The main
problems with studies on the genetic background of PEX have been the asymptomatic nature
of PEX and late age of onset which make it difficult to collect multi-generation families with
several affected individuals for linkage and association studies. A wide variety of inheritance
models have been suggested depending on the study material [39] and, of these, the autosomal
dominant mode of inheritance with incomplete penetrance has received the most support
[40,41]. However, most of these studies investigating PEX inheritance have been based on small
pedigrees making hypotheses about the inheritance model uncertain. Thorleifsson et al. [42]
explained the genetic aetiology of PEX in virtually all instances. In Iceland and Sweden, the
high-risk haplotype is very common with a frequency that averages about 50% in the general
population; approximately 25% are homozygous (two copies) for the haplotype with the
highest risk.
Apolipoprotein E (APOE) is the major apolipoprotein in the central nervous system, which
plays important role in the uptake and redistribution of cholesterol within neuronal network
[43]. Immunologically, APOE is present in many cerebral and systemic amyloidoses; such as
late-onset Alzheimer’s disease, Down’s syndrome, and prion disorders. It is thought that
APOE can promote the aggregation of amyloidogenic proteins into the β-pleated sheet
conformation that is typical of all amyloid deposits, and is directly involved in the amyloid
deposition and fibril formation [44,45]. This widespread association of APOE with biochemi‐
cally diverse amyloids has led scientists to postulate a more general role for it in the process
of amyloid formation.
APOE is synthesized by Muller cells (the predominant glial cells of the retina) and released
into the vitreous and then transported into the optic nerve through anterograde rapid transport
where it has an important role in axonal nutrition [46]. It has been suggested that APOE plays
a role in neuronal survival following ischemia and other chemical insults and particular APOE
isoform may be related to neuronal degeneration in glaucoma [47]. APOE, is a 34-kDa
glycosylated protein, composed of 299 amino acids encoded by a four exon polymorphic gene
on chromosome 19q13.2. The gene encoding APOE has three polymorphic variants in human
designated as ε2, ε3, and ε4. These variants differ from one another by the presence of either
C or T nucleotide at codons 112 and 158. These three alleles encode different APOE isoforms
which vary significantly in structure and function including receptor binding capacity and
lipid metabolism [48]. As each individual human being carries two allelic copies in a gene, six
possible genotypes (ε2/ε2, ε3/ε3, ε2/ε3, ε3/ε4, ε2/ε4, and ε4/ε4) are formed by different
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combinations of these three alleles. The frequency of these genotypes differ significantly
among different ethnic groups, however, APOE ε3/ε3 is the most predominant genotype and
ε3 the most common allele in majority of populations [49-51]. The ε3 allele is considered to be
the ancestral allele; and ε2 and ε4 are considered as variants, on the basis of single point
mutations. Global studies on the APOE locus have shown highly significant variations in the
allele frequencies of ε2, ε3, and ε4 [52-58].
The complex genetic contributions to glaucoma and PEX have been attributed to the effects of
individual causative mutations as well as interactions of multiple genes with a variety of
environmental factors. However, most of the identified genes do not appear to have a major
role in the complex phenotype. Recent whole genome–association studies have successfully
identified a number of single nucleotide polymorphisms as genetic factors conferring sus‐
ceptibility to complex diseases, such as age-related macular degeneration, and it is expected
that this will be a useful approach for glaucoma and PEX as well.
Earlier studies clearly point towards a possible association between APOE alleles and glau‐
coma. However, the results of these studies are contradictory. Some investigators suggested
positive association [47,59,60] while others have shown no link at all [61-63]. Moreover, earlier
studies were mainly restricted to white populations from Australia [47], United Kingdom
[62,63] and Sweden [61] with only few reports from other ethnic groups restricted to Chinese
and Japanese [59,60,64,65]. Similarly APOE polymorphism and the presence of ε 2 alleles have
been reported to be significantly associated with the development of PEX in Turkish patients
[66]. However, APOE genotypes and PEX seems to differ among study populations and no
significant differences in allele and genotype frequencies between PEX and control were
observed in European patients from Norway [67] and Germany [68]. Moreover, the informa‐
tion about the association of APOE alleles with glaucoma and PEX in Arabs is very limited.
Therefore, this study on underlying genetics in these complex disorders will help analyze the
genetic aspect of PEX and glaucoma in Saudi patients. In this study, we evaluated the possible
association of alleles/genotypes of APOE with primary glaucoma (POAG and PACG) and PEX
in Saudi population.
2. Methods
2.1. Subjects
The present study was undertaken to evaluate the association of APOE allele and genotype in
Saudi primary glaucoma and pseudoexfoliation syndrome patients. A total of 200 unrelated
Saudi patients with primary glaucoma [primary open angle glaucoma (POAG) and primary
angle closure glaucoma (PACG)] and 51 pseudoexfoliation syndrome (PEX) were recruited
from ophthalmology clinic of the Riyadh Military Hospital, Saudi Arabia. The glaucoma
patient group consisted of 100 males and 100 females, with age at diagnosis ranging from 30
to 78 years (mean ± SD: 58±14.4). The control group consisted of 200 unrelated subjects, with
160 males and 40 females, ages ranging from 20 to 58 years (mean ± SD: 45±11.6). The diagnosis
of PG was based on clinical observations:
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A comprehensive eye examination was done that included best-corrected visual acuity (BCVA)
measurements using logarithm of the minimum angle of resolution (logMAR) 4-m charts
(Light House Low Vision Products, New York, NY), applanation tonometry, gonioscopy,
dilated fundus examination, optic disc photography, and visual field (VF) examination. On
gonioscopy, an angle was considered occludable if the pigmented trabecular meshwork was
not visible in >180° of angle in dim illumination. Laser iridotomy was performed in subjects
with occludable angles after consent was obtained, and they had the rest of the examination
on some other day.
2.2. Visual fields
Automated VFs were performed for all the subjects with BCVA of 4/16 (logMAR 0.6) or better,
using frequency-doubling perimetry (Carl Zeiss Meditec, Inc., Dublin, CA). All eligible
subjects underwent C-20-1 screening (if the results were unreliable or abnormal, the test was
repeated) and the N-30 threshold test. The reliability criteria were no fixation or false-positive
errors for the C-20-1 screening test and < 20% fixation errors and <33% false-positive and false-
negative errors for the threshold N-30 test. Visual fields with no depressed points to any level
of sensitivity were considered to be normal. A provisional diagnosis of suspected glaucoma
was made when the subject had one or more of the following conditions: intraocular pressure
(IOP) ≥ 21 mmHg in either eye; vertical cup-to-disc ratio (VCDR) ≥ 0.7 in either eye or CDR
asymmetry ≥ 0.2; and focal thinning, notching, or a splinter hemorrhage. All these subjects
were asked to perform a threshold VF test using the Swedish interactive threshold algorithm
Standard 30-2 program (model 750, Carl Zeiss Meditec). A glaucomatous field defect was
diagnosed using a single reliable threshold VF examination of the central 30° (Swedish
interactive threshold algorithm Standard 30-2). The field was considered to be abnormal if the
glaucoma Hemi-field test results were outside normal limits and ≥3 abnormal contiguous non-
edge points (except the nasal horizontal meridian) were depressed to P< 5% [69]. Reliability
criteria were as recommended by the instrument’s algorithm (fixation losses <20%; false-
positive and false-negative < 33%).
2.3. Diagnostic definitions
The distribution of VCDR and IOP was obtained from those subjects with reliable and normal
supra-threshold VF testing using frequency-doubling perimetry. Cases of glaucoma were
defined using the International Society of Geographical and Epidemiologic Ophthalmology
classification [70]. Glaucoma was classified according to 3 levels of evidence. In category 1,
diagnosis was based on structural and functional evidence. It required CDR or CDR asym‐
metry ≥ 97.5th percentile for the normal population or a neuroretinal rim width reduced to ≥
0.1 CDR (between 11- and 1-o’clock or 5- and 7-o’clock) with a definite VF defect consistent
with glaucoma using the Swedish interactive threshold algorithm 30-2. Category 2 was based
on advanced structural damage with unproved field loss. This included those subjects in whom
VFs could not be determined or were unreliable, with CDR or CDR asymmetry ≥ 99.5th
percentile for the normal population. Lastly, category 3 consisted of persons with an IOP ≥
99.5th percentile for the normal population, whose optic discs could not be examined because
of media opacities.
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Blindness was defined as a best-corrected logMAR visual acuity of < 2/40 (log MAR 1.3) and/or
constriction of the VF to <10° from fixation in the better eye [71]. Hyperopia was defined as
spherical equivalent > 0.50 diopter (D) in a phakic eye [72]. Diabetes mellitus was detected based
on current use of antidiabetic medication and/or random blood sugar level > 200 mg/dl [73]. Thus
the primary Glaucoma patients were separated in two groups (POAG and PACG) as follows:
POAG: Anterior chamber angles open and appearing normal by gonioscopy, typical features
of glaucomatous optic disc as defined earlier, and visual field defects corresponding to the
optic disc changes.
PACG: At least two of the criteria mentioned: glaucomatous optic disc damage or glaucoma‐
tous visual field defects in combination with anterior chamber angle partly or totally closed,
appositional angle closure or synechiae in angle, absence of signs of secondary angle closure
(e.g., uveitis, lens related glaucoma; microspherophakia; evidence of neovascularization in the
angle and associated retinal ischemia or congenital angle anomalies). Patients with signs of
intracranial disease that would cause optic nerve atrophy in x-ray computerized tomography
or magnetic resonance imaging were excluded.
Diagnosis of PEX among Saudi patients visiting Primary Care Clinics of Riyadh Military
Hospital was undertaken by a team of ophthalmologists. Patients visiting primary care clinic
were offered free eye examination to exclude the presence of PEX. Consent was obtained from
the patients after describing them the features of PEX syndrome. Patients who suffered ocular
trauma or with active eye condition, and/or has undergone ocular surgery were excluded from
this study.
All patients were subjected to interviews and initial evaluation was performed by the oph‐
thalmic assistant (OA). Demographic data were collected, complaints of the eye and family
history of eye problems were recorded. Visual acuity was recorded. After the preliminary
examination and interview all patients were examined by an ophthalmologist for identifying
the factors for PEX syndrome by the external eye examination: PEX flakes on pupil margin
(undilated examination), Iris transillumination defects, evaluation of anterior chamber depth
by Van Herick’s technique, measurement of intraocular pressure, poor pupil dilation, and
examination of the crystalline lens surface after papillary dilation for the presence of PEX
material. After identification of PEX, the patients were short listed and further rechecking and
confirmation of PEX syndrome was performed by (1) slit lamp examination of the anterior
segment which included flakes on the pupillary margin, iris transillumination defects, flare in
the A/C and corneal edema, (2) measurement of intraocular pressure (IOP) with Goldman
tanometer (3) gonioscopy to record angle depth PEX flakes and/or hyperpigmentation on the
trabecular meshwork which was followed by examination after dilation which included Poor
pupillary dilation, flakes on the anterior lens capsule, posterior synechiae, lens opacity,
phacodenesis and lens subluxation, bilaterality and symmetry and optic nerve head cupping.
Out of 51 confirmed cases of PEX 25 were males and 26 females. The average age of PEX
positive males and females patients was 70.43±9.62 years and 65.56±7.45 years respectively.
Venous blood was collected from the confirmed PEX and PG patients as well as healthy
controls, stored at -20ºC before extraction of DNA. The study protocol was approved by the
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Ethics Committee of the Hospital, and written informed consent was obtained from all study
participants.
2.4. Genotyping
The genotypes of the APOE polymorphisms were determined using APOE StripAssayTM kit
based on polymerase chain reaction (PCR) and reverse-hybridization technique (ViennaLab
Labordiagnostika GmbH, Vienna, Austria). The procedure included three steps: (1) DNA
isolation, (2) PCR amplification using biotinylated primers, (3) hybridization of amplification
product to a test strip containing allele-specific oligonucleotide probes immobilizd as an array
of parallel lines. Bound biotinylated sequences were detected using streptavidin- alkaline
phosphatase and color substrates. To cross-check the results the genotypes of the APOE
polymorphisms were also determined by PCR and restriction fragment length polymorphism
(RFLP) technique. Primers were designed on the basis of the sequence data for APOE available
in the GenBank to amplify the coding sequence of APOE. PCR was performed using PuRe Taq
Ready-To-Go PCR Beads (Amersham, USA) with following primers:
Forward primer: 5- GAC GCG GGC ACG GCT GTC CAA GGA GCT GCA GGC
GAC GCA GGC CCG GCT GGA CGC GGA CAT GGA GGA-3
Backward primer: 5 - AGG CCA CGC TCG ACG CCC TCG CGG GCC CCG GCC
TGG TAC ACT-3
Genomic DNA was extracted from whole blood using a commercial kit (Qiamp; Qiagen,
Hiden, Germany). The 200–300 ng of genomic DNA was used as a template in 25 μl reaction.
Genomic DNA was amplified for 40 cycles. Each cycle consisted of: 94 °C for 30 sec, 68 °C for
10 sec, 72 °C for 1 min; PCR products obtained were separated by electrophoresis on 1.5%
agarose gel in TAE buffer, visualized by ethidium bromide fluorescence. Fragments with the
expected size were cut from the gel, purified using GFX PCR DNA Gel band purification kit
(Amersham, USA). Purified DNA was digested with Cfo I (Hha I) enzyme, separated by
agarose gel electrophoresis to identify the genotype. On the basis of size and number of various
fragments generated, APOE genotypes were determined as ε2/ε2 with 144 bp and 96 bp,
ε3/ε3 with 144 bp and 48 bp, ε4/ ε4 with 72 bp and 48 bp, ε2/ε3 with 144 bp, 96 bp and 48 bp,
ε3/ ε4 with 144 bp, 72 bp and 48 bp, and ε2/ε4 with 144 bp, 96 bp, 72 bp and 48 bp fragments.
The prevalence of various genotypes in patients and controls was determined. Complete
matching of results was obtained following both of the above mentioned procedures.
2.5. Statistical analysis
Frequencies of various alleles and genotypes for each polymorphism were compared between
patients and controls and analyzed by Fisher’s exact test and the P-values < 0.05 were consid‐
ered as significant. The strength of the association of disease with respect to a particular allele/
genotype is expressed by odd ratio interpreted as relative risk (RR) according to the method of
Woolf as outlined by Schallreuter et al [74]. The RR was calculated only for those alleles and
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genotype which were increased or decreased in patients as compared to normal Saudis. The
RR was calculated for all the subjects using the formula given below:
RR = (a) × (d)/(b) × (c)
a = number of patients with expression of allele or genotype
b = number of patients without expression of allele or genotype
c = number of controls with expression of allele or genotype
d = number of controls without expression of allele or genotype.
Etiologic Fraction (EF): The EF indicates the hypothetical genetic component of the disease.
Values 0.0-0.99 are of significance. It was calculated for positive association (RR>1) using the
following formula [75].
EF = (RR-1)f/RR, where f = a/a+c
Preventive Fraction (PF): The PF indicates the hypothetical protective effect of one specific
antigen for the disease. It was calculated for negative association only where RR<1 using
following formula [75].
PF = (1-RR)f/RR (1-f) + f, where f = a/a+c
Values <1.0 indicated the protective effect of the genotype/ allele against the manifestation of
disease.
3. Results
Out of 200 PG patients 134 were diagnosed as having POAG and 66 as having PACG. Diagnosis
of POAG was based on category 1 in 20 subjects (14.93 %) and category 2 in 114 subjects (85.07
%). Between category 1 and category 2 there was no significant different in age, IOP and gender
distribution. One subject was blind in both eyes and 1 subject had unilateral blindness due to
POAG. There were 66 subjects with PACG. Diagnosis was based on category 1 in 16 subjects
(24.24%), category 2 in 46 subjects (69.70%), and category 3 in 4 subjects (6.06%). Three subjects
(4.55 %) bilaterally, 4 (6.06 %) were unilaterally blind due to PACG.
The results of frequency of APOE alleles and genotypes in the PG patients and the control
subjects are summarized in Tables 1, 2,3,4,5 and 6. The frequency of the ε3 alleles was signif‐
icantly lower in the glaucoma patients (86.5 %) compared to the control subjects (95.75 %,
P=0.0001, RR=0.284, PF=0.544). On the other hand the frequencies of the ε4 allele was signifi‐
cantly higher in the glaucoma patients as compared to controls (12.25% vs 4.25%, P=0.0001,
RR=3.145, EF=0.506). The allele ε2 was present only in 5 patients while totally absent in control
groups (Table 1).
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Allele
Glaucoma (N=400) Control (N=400)
P-value RR EF*/PF
Number Frequency (%) Number Frequency(%)
ε4 49 12.25 17 4.25 0.0001‡ 3.145 0.506*
ε3 346 86.50 383 95.75 0.0001‡ 0.284 0.544
ε2 5 1.25 0 0.0 0.030‡ - -
N, number of alleles; RR, relative risk; EF, etiological fraction; PF, preventive fraction; ‡, statistically significant
Table 1. Distribution of APOE allele frequencies in glaucoma patients and matched control subjects.
Our study on various genotypes of APOE also showed variations in patient and control groups
(Table 2). The prevalence of ε3/ε3, ε3/ε4, ε4/ε4, ε2/ε3, and ε2/ε4 was 75.5, 20.5, 1.5,1.5 and 1.0%
in patients and 91.5, 8.5, 0,0 and 0 % in control group respectively.
Genotype
Glaucoma (N=200) Control (N=200)
P-value RR EF*/PF
Number Frequency (%) Number Frequency (%)
ε3/ε3 151 75.50 183 91.50 0.0001‡ 0.286 0.530
ε3/ε4 41 20.50 17 8.50 0.0006‡ 2.775 0.491*
ε4/ε4 3 1.50 0 0.0 0.1240 - -
ε2/ε3 3 1.50 0 0.0 0.1240 - -
ε2/ε4 2 1.00 0 0.0 0.2493 - -
ε2/ε2 0 0.0 0 0.0 - - -
N, number of subjects; RR, relative risk; EF, etiological fraction; PF, preventive fraction; ‡, statistically significant
Table 2. Distribution of APOE genotypes in glaucoma patients and matched controls
Though the frequency of ε3/ε3 genotype was higher in both the test and control Saudi
population, the statistical analysis of data showed strongly significant difference in ε3/ ε3
genotype frequencies between patients and controls (P=0.0001, RR=0.286, PF=0.53). The
difference in the frequencies of the second common genotype (ε3/ ε4) was also statistically
significant between the two groups (P=0.0006) being more in glaucoma patients. Genotypes
ε4/ε4, ε2/ε3 were found only in 1.5% and ε2/ε4 in 1% of patients while being completely absent
in the controls (P=0.124). The genotypes ε2/ε2 was absent in both patient and control groups.
These results indicated that allele ε4 and genotype ε3/ ε4 are associated with glaucoma and
can be a risk factor while allele ε3 and genotype ε3/ ε3 may be protective in Saudis. The
frequencies of various genotypes and alleles were not significantly different in male and female
patients clearly indicating that gender plays no role in genotype/ allele distributions among
populations (Table 3).
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Genotype/Allele
Male (N=100) Female (N=100)
P-value
Number Frequency (%) Number Frequency (%)
ε3/ε3 71 71.00 80 80.00 0.143
ε3/ε4 26 26.00 15 15.00 0.079
ε4/ε4 0 0.0 3 3.00 0.123
ε2/ε3 2 2.00 1 1.00 0.623
ε2/ε4 1 1.00 1 1.00 0.999
ε3 170 85.00 176 88.00 0.385
ε4 27 13.50 22 11.00 0.451
ε2 3 1.50 2 1.00 0.685
N, number of subjects
Table 3. Distribution of APOE genotypes and alleles in male and female glaucoma patients
Though the distribution of APOE genotypes and alleles was not significantly different in two
types of glaucoma (Table 4) however when compared with controls separately, significant
difference was found in the frequencies of genotypes ε3/ε4, ε3/ε3 and alleles ε4 and ε3 in POAG
and controls.
Genotype/Allele Open angle glaucoma (134)N (%)
Angle closure glaucoma (66)
N (%) P-value
ε3/ε4 30 (22.39) 11 (16.66) 0.456
ε4/ε4 3 (2.24) 00 0.552
ε3/ε3 98 (73.13) 53 (80.30) 0.298
ε2/ε3 2 (1.49) 1 (1.52) 1.000
ε2/ε4 1 (0.75) 1 (1.52) 0.552
ε4 37 (13.81) 12 (9.09) 0.197
ε2 3 (1.12) 2 (1.52) 0.666
ε3 228 (85.07) 118(89.39) 0.277
N, number of subjects
Table 4. Comparison of APOE genotype/ allele frequencies in patients with POAG and PACG
The frequency of genotype ε3/ ε4 and ε 4 allele was significantly more (P= 0.0006 and 0.0001
respectively) in POAG patients as compared to controls (Table 5).
Glaucoma - Basic and Clinical Aspects138
Genotype/Allele Open angle glaucoma (134)N (%)
Controls (200)
N (%) p-value RR EF*/PF
ε3/ε4 30 (22.39) 17 (8.50) 0.0006‡ 3.105 0.432*
ε4/ε4 3 (2.24) 00 0.063 - -
ε3/ε3 98 (73.13) 183 (91.50) 0.0001‡ 0.252 0.507
ε2/ε3 2 ( 1.49 ) 00 0.160 - -
ε2/ε4 1 ( 0.75 ) 00 0.401 - -
ε4 37 ( 13.81) 17(4.25) 0.0001‡ 3.608 0.495*
ε2 3 ( 1.12 ) 00 0.064 -
ε3 228 (85.07 ) 383 (95.75) 0.0001‡ 0.253 0.524
N, number of subjects; RR, relative risk; EF, etiological fraction; PF, preventive fraction; ‡, statistically significant
Table 5. Distribution of APOE genotype/ allele frequencies in patients with POAG and matched controls
The frequency of allele ε3 and ε3/ε3 genotype was significantly higher in controls (P=0.0001).
Similarly, the frequency of various genotypes of APOE differ between PACG and controls but
the differences were not statistically significant except for ε3/ε3(P=0.022) (Table 6). However,
the frequency of allele ε4 was higher in PACG whereas ε3 in controls indicating that the allele
ε4 is also significantly associated with PACG in Saudis while genotype ε3/ε3 and allele ε3 may
be protective.
Genotype/Allele Angle closure glaucoma (66)N (%)
Controls (200)
N (%) P-value RR EF*/PF
ε3/ε4 11 ( 16.66 ) 17 (8.50) 0.067 2.152 0.210*
ε4/ε4 0 00 - - -
ε2/ε3 1 (1.52) 00 0.248 - -
ε2/ε4 1 (1.52) 00 0.248 - -
ε3/ε3 53 ( 80.30 ) 183 (91.50) 0.022‡ 0.378 0.269
ε4 12 ( 9.09 ) 17(4.25) 0.045‡ 2.252 0.229*
ε2 2 ( 1.52) 00 0.061 - -
ε3 118(89.39 ) 383 (95.75) 0.010‡ 0.374 0.282
N, number of subjects; RR, relative risk; EF, etiological fraction; PF, preventive fraction;
Table 6. Distribution of APOE genotype/ allele frequencies in patients with PACG and matched controls
Over all prevalence of PEX in our study was 3.03%. Unilateral PEX was noted in 38% while
bilateral PEX in 62% of the PEX patients (Figures.1 & 2). However, there was no significant
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difference in the prevalence of PEX in male and female. Prevalence distribution of PEX with
the age in Saudi population is summarized in (Table 7). The prevalence of PEX varied from
0.50% to 25% in various age groups. The majority of the patients screened was in the age group
of 50-60 years followed by those from <50 years¸ 61-70 years, 71-80 years and 81-100 years
groups. The prevalence of PEX increased with progressing of age.
Age group (years) Patients screened (N) PEX positive patients (N) Frequency of PEX (%)
<50 600 3 0.50
51-60 850 27 3.17
61-70 200 16 8.00
71-80 30 4 13.33
81-100 4 1 25
Total 1684 51 3.03
N, number of patients
Table 7. Age specific prevalence of PEX in Saudi patients
 
Figure 1. Showing massive PEX material in the papillary area forming a membrane like deposit
The results of frequency of APOE alleles and genotypes in the PEX patients and the control
subjects are summarized in Tables 8 and 9. The frequency of the ε3 alleles was significantly
lower in the PEX patients (82.35 %) compared to the control subjects (95.75 %, P=0.0001,
RR=0.207, PF=0.373). On the other hand the frequencies of the ε2 and ε4 allele were significantly
higher in the PEX patients as compared to controls (2.94% vs 0.00%, P=0.0081 and 14.70% vs
4.25%, P=0.0004, RR=3.884, EF=0.347 respectively). The allele ε2 was absent in control group
(Table 8).
Glaucoma - Basic and Clinical Aspects140
Allele
Pseudoexfoliation (N=102) Control (N=400)
P-value RR EF*/PF
Number Frequency (%) Number Frequency(%)
ε4 15 14.70 17 4.25 0.0004‡ 3.884 0.347
ε3 84 82.35 383 95.75 0.0001‡ 0.207 0.373
ε2 3 2.94 0 0.0 0.0081‡ - -
N, number of subjects; RR, relative risk; EF, etiological fraction; PF, preventive fraction; ‡, statistically significant
Table 8. Distribution of APOE allele frequencies in PEX patients and matched controls
Our study on various genotypes of APOE also showed variations in PEX patient and control
groups (Table 9). The prevalence of ε3/ε3, ε3/ε4, ε4/ε4, ε2/ε3 and ε2/ε4 was 70.58, 21.56, 1.96,
1.96 and 3.92% in patients and 91.5, 8.5, 0, 0, and 0 % in control group respectively. Though
the frequency of ε3/ε3 genotype was high in both the test and control Saudi population, the
statistical analysis of data showed significant difference in ε3/ ε3 genotype frequencies between
patients and controls, being more in controls than patients (P=0.0002, RR=0.222, PF=0. 363).
The difference in the frequencies of the second common genotype ε3/ ε4 was also statistically
significant between the two groups and was found to be increased in PEX patient group
(P=0.012, RR=2.96, EF=0.259). Genotypes ε4/ε4, ε2/ε3 and ε2/ε4 were found only in patients
while being completely absent in the controls. The genotype ε2/ε2, was absent in both the
groups (Table 9).
These results indicated that alleles ε4 and ε2 and genotype ε3/ ε4 and ε2/ε4 were associated
with PEX and can be a risk factor while allele ε3 and genotype ε3/ ε3 may be protective in
Saudis. The frequencies of various genotypes and alleles were almost similar in male and
female patients clearly indicating that gender plays no role in genotype/ allele distributions
among populations.
 
Figure 2. Shows deposition of PEX material more peripherally indicating wide pupillary excursion
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4. Discussion
The result of this study showed a very high frequency (95.75%) of allele ε3, very low frequency
(4.25%) of ε4 and absence of allele ε2 in control population. Global studies on APOE locus have
shown highly significant variations in allele frequencies among various populations. Studies
from various geographical locations and ethnicities have reported a wide range of frequencies
of ε2 (0-12%), ε3 (75-90 %) and ε4 (6-20%) [52-58]. The differences in the APOE genotype/allele
frequencies in different populations may be attributed to environmental factors as well as
genetic differences. The ε3 allele is the most frequent in all the human groups, especially in
populations with a long established agricultural economy, whereas APOE ε4 allele remains
higher in populations where the economy of foraging still exists or food supply is/was scarce
and sporadically available [76]. Data on APOE allele frequencies collected from literature
showed that the APOE allele distributions were different between North and South Europe.
Additionally, compared to northern European countries, Mediterranean countries such as
Italy, Turkey and Greece had lower frequencies of APOE- ε2 and ε4 alleles [77-79].
Results of present study revealed significant differences in the frequencies of ε3 and ε4 alleles
in glaucoma patient as compared to control groups (Table 1). Allele ε3 being more common
in controls while ε4 was predominant in glaucoma patients suggesting that the inheritance of
the ε4 allele might be a risk factor whereas ε3 might exert a protective effect for glaucoma in
Saudi population. Neuroprotective effect of ε3 is also evident from several earlier studies.
APOE has an isoform specific effect on neuronal growth with ε3 stimulating neuronal
elongation and neurite outgrowth on dorsal root ganglion [80]. In individuals with acute
cerebral ischemia, such as an intracerebral hemorrhage, the ε3 allele confers a much higher
survival and functional recovery whereas ε4 leads higher rate of disability and mortality [81].
Our results clearly suggest that presence of ε4 is associated with high risk of both POAG and
PACG. Vickers et al [47] also reported an association between the ε4 allele and NTG in the
Tasmanian population. Recently, Yaun et al [65] reported that the ε4 may be a latent risk factor
in developing primary glaucoma in Chinese population. On the other hand Liew et al [82]
Genotype
Pseudoexfoliation (N=51) Control (N=200)
P-value RR EF*/PF
Number Frequency (%) Number Frequency (%)
ε3/ε3 36 70.58 183 91.50 0.0002‡ 0.222 0.363
ε3/ε4 11 21.56 17 8.50 0.012‡ 2.960 *0.259
ε4/ε4 1 1.96 0 0.0 0.203 - -
ε2/ε2 0 0 0 0.0 - - -
ε2/ε3 1 1.96 0 0.0 0.203 - -
ε2/ε4 2 3.92 0 0.0 0.040‡ - -
N, number of subjects; RR, relative risk; EF, etiological fraction; PF, preventive fraction; ‡, statistically significant
Table 9. Distribution of APOE genotype frequencies in PEX patients and matched controls
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found a weak association between APOE ε4 and retinal microvascular degeneration. Contrary
to these findings a decrease risk of NTG in Chinese [59,60] and POAG in Japanese with ε4 allele
[64] has been reported, whereas some investigators reported no link between APOE polymor‐
phism and glaucoma [61,62].
Besides glaucoma, APOE ε4 allele has been identified as a genetic susceptibility factor for a
variety of neurodegenerative disorders in diverse ethnic populations [83-86 ]. APOE ε4 allele
has also been associated with early age-at-onset of AD in a dose dependent manner [87,88].
Interestingly, a high incidence of glaucoma in AD patients clearly suggests a close association
between ophthalmic and neurodegenerative disorders [89,90]. It has been hypothesized that
the cellular mechanisms involved in the degeneration of optic nerve cells in glaucoma are quite
similar to the neurodegenerative changes in AD [47,91,92]. APOE allele ε4 is also strongly
linked with increased risk of Parkinson’s disease, schizophrenia and coronary artery disease
[93-99]. Possession of the ε4 allele is also associated with a retarded recovery after traumatic
head injury [100,101]. The exact mechanism by which APOE ε4 exerts its deleterious effect is
far from clear. However, APOE alleles has been reported to modulate the biological functions
of APOE in part by altering the binding of the different lipoprotein lipid classes [93]. Individ‐
uals carrying the ε4 allele have higher plasma and neuronal levels of cholesterol as compared
to individuals with ε2 or ε3. APOE immunoreactivity has been localized to basal laminar
deposits and soft drusen in age related macular degeneration [102]. APOE has also been
localized to the Müller cells (specialized retinal glia) [46,102] and this protein may be increased
in Müller cells in glaucomatous eyes [103], indicating that this glial cell may have a role in the
retinal response to glaucomatous injury.
On the other hand, earlier genetic studies support the concept that APOE would directly be
involved in the amyloid deposition and fibril formation; and they suggest a close association
between one of the main isoforms of APOE encoded by the ε4 allele and both familial and
sporadic late-onset Alzheimer’s disease (AD) [44,45]. In addition, deposits in various amy‐
loidoses and prion diseases such as Down’s syndrome, cystatin C-related Icelandic-type
hereditary amyloid angiopathy, Creutzfeldt-Jakob disease, Lewy body dementia, dementia in
Parkinson’s disease include both biochemically and immunohistochemically detectable
amounts of APOE [104-107].
The higher frequency of ε3/ ε3 in controls as compared to the patients indicated a protective
effect of ε3/ ε3 on development of glaucoma in Saudis. Though the genotypes ε4/ε4, ε2/ ε3 and
ε2/ε4 were only found in glaucoma patients and completely absent in normal Saudi population
however, the differences were statistically insignificant. The genotypes ε2/ε2, was absent in
both patients and control group. Earlier studies on APOE polymorphism in general healthy
population also showed absence of genotypes containing ε2 allele among Saudis [51,108] as
well as Native Americans [109].
This study showed that prevalence of PEX in Saudi Population was 3.03%. No significant
difference was found in prevalence of PEX between male and female whereas the rate of
prevalence varied in different age group. the prevalence of PEX increased with progressing of
age. Earlier investigators from Saudi Arabia using a very small hospital based study reported
overall prevalence of PEX as 9.3% [110]. PEX occurs worldwide, although reported prevalence
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rates vary extensively with geographical  location,  as well  as with ethnicity [21,111].  The
prevalence of PEX varies significantly among Asians. The prevalence of PEX has been report‐
ed to be 3.01% and 6.28% in two different age groups in Southern Indian population [112], 6.45
% in Pakistani population [113], 3.4% in Japanese [114], 0.4% in Chinese [115] and 0.2 to 0.7% in
Chinese Singaporeans [116]. In Scandinavia, the prevalence among persons over age 60 varies
from over 20% in Finland to about 25% in Iceland. Aasved [117] found prevalence of 6.3%, 4.0%,
and 4.7% in persons over age 60 in Norway, England, and Germany, respectively. Forsius [118]
studied prevalence in patients over age 60 years in varied groups and found prevalence ranging
from 0% in Greenland Eskimos to 21% in Icelanders. Lantukh and Piatin [119] found a low
prevalence in native Siberian Tchutchee, but a much higher rate among immigrants to the area
indicating ethnic variations. Similarly in New Mexico, Spanish-American men are nearly six
times as likely to develop PEX than are non-Spanish-Americans [120].
The prevalence of PEX may also vary within the same country in similar environments and
over short distances as found in present study. Similarly, in France the prevalence in over age
70 years varies from 3.6% in Toulon to 20.6% in Brest [121]. Ringvold et al [122] also found
rates of 10.2%, 19.6%, and 21.0% in three closely situated municipalities in central Norway.
The reasons underlying true variations, both from one population to another and within more
or less homogeneous populations, remain to be explained. Geographic distribution patterns
may perhaps be explained either by regional gene pools or by environmental influences.
Persons living at lower latitudes (Greece, Saudi Arabia, and Iran) appear to develop PEX at
younger ages [123]. Exposure to sunlight (ultraviolet radiation) may or may not be implicated.
Forsius and Lukka [124] found no PEX in Eskimos versus 20% among Lapps living at the same
latitude.
Similar to our observations, the prevalence of PEX increases with age in most of the studies
[112,114,117]. Forsius [125] found PEX incidence to double every decade after age 50. These
variations in prevalence rates may consequently be caused, to varying degrees, by genuine
differences in genetic, ethnic and environmental factors and by methodological differences in
age and sex distribution, diagnostic criteria, experience of the examiners in diagnosing the
syndrome and the thoroughness of their examination [126].
This study also indicated that allele ε4 was associated with PEX and can be a risk factor while
allele ε3 may be protective for PEX similar to PG in Saudi patients. Allele ε2 was found in only
2.94% of the PEX while totally absent in controls. Contrary to our results, Yilmaz et al [66]
reported a close association of ε2 allele with PEX in Turkish population. According to them
PEX have significantly higher frequency of ε2 allele (50%). In their study the frequency of
genotypes carrying ε2 allele was also significantly higher in PEX. They have suggested that
especially when ε2 allele is heterozygous, the possibility of developing PEX increases which
could be an indicator for pathogenicity when this allele frequency is over 30% in the PEX group.
In our study ε2/ ε3 and ε2/ ε4 genotypes are found only in 1 and 2 cases respectively. As the
genotype frequencies are low in these groups, it is difficult to make general conclusion on
statistically insignificant data.
On the other hand our results for APOE polymorphism in PEX indicated that genotype ε3/ ε4
was also associated with PEX (P=0.012) and can be a risk factor while genotype ε3/ ε3 may be
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protective for PEX (P=0.0002) similar to PG in Saudi patients. In addition, the control group
had a significantly higher frequency of the ε3 allele (95.75%) than the PEX group (82.35%),
showing that this allele had a protective effect for developing the disease (P=0.0001). This is in
agreement with Yilmaz et al [66] who reported a protective role of APOE ε3 allele in patients
with exfoliation syndrome in Turkish population. However there are reports indicating no
association of APOE genotypes and PEX in Germans or Italians [68] and Norwegians [67].
In the literature, ε 4 allele has been shown to be risky for developing amyloidoses in AD
[44,45,104,106,107]. Yilmaz et al [66] suggested PEX to belong to the amyloidosis group
depending on the deposition of amyloid or amyloid-like material throughout the body. As
stated earlier inheritance of the ε4 allele has also been associated with elevated risk to Alz‐
heimer’s disease. In this regard, it is interesting that visual deficits have been reported in
Alzheimer’s disease cases. However, there are conflicting reports as to whether visual field
loss observed in a relatively high proportion of Alzheimer’s disease cases is associated with
retinal or central damage [127-129]. It has also been noted that both Alzheimer’s disease and
Parkinson’s disease cases have increased glaucomatous retinal changes [90]. In the light of the
these findings, there may be similar cellular processes involving APOE related to neuronal
damage. It has been argued that both Alzheimer’s disease and glaucoma/PEX are ultimately
axon damaging conditions and it is how nerve cells respond to this injury that leads to overall
neuronal degeneration and the clinical picture of progressive loss of function [130]. Müller
cells that express particular APOE isoforms may thus have an important role in regulating the
response of retinal ganglion cells to injury. However, it cannot be ruled out that APOE may
be acting centrally to promote β-amyloid fibril formation in structures such as the lateral
geniculate nucleus [131] and that these plaques are causing damage to retinal axons and visual
pathways. In this regard, it would be intriguing to determine whether glaucoma and PEX cases
may have a higher incidence of Alzheimer-type dementia.
The result of this study suggests that APOE alleles may influence the risk of glaucoma and
PEX. The inheritance of the ε4 allele is associated with elevated risk of POAG, PACG and PEX
and ε3 may exert protection for both type of glaucoma as well as PEX. Genotypes containing
allele ε2 (ε2/ε3, ε2/ε4) were found only in small number of patients (3POAG, 2 PACG and
1PEX) whereas altogether absent in Saudi normal population so it is difficult to derive any
conclusion. Further studies involving larger number of patients from different race/tribes of
Saudi Arabia are warranted to reach any definite conclusion as the APOE allele frequencies
from same population (Turkish) reported by different authors are not uniform [66,132,133].
These differences in the distribution of APOE allele and genotype in single population in
different studies have been attributed to geographical/ racial differences and/ or variations in
genotyping methodology.
Though the inheritance of the ε4 allele seems to be associated with elevated risk of primary
glaucoma and PEX in our Saudi population. However, it will be important to replicate these
results in populations from other geographical locations of Saudi Arabia. The significance of
inheritance of these APOE allelic isoforms has yet to be established, as is the case for the
potential role of this protein in many other neurodegenerative conditions, but it may be linked
with associated hypertension, formation of central β-amyloid deposits or a more general role
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in the regulation of lipids following axonal injury. However, our results together with similar
data elucidated a potential overlap between the degenerative pathways underlying glaucoma/
PEX and Alzheimer-type dementia and brain injury.
5. Conclusion
This study clearly showed that the APOE polymorphism represents a major risk factor for
ophthalmic/neurodegenerative diseases and this study together with previous studies pointed
to a possible association between APOE alleles and PG/PEX in defined populations. However,
the association between APOE genotype and PG/PEX seems to differ among studied popula‐
tions, indicating a modifying rather than a direct genetic effect. Although our results indicated
ε4 allele to be significantly associated with the development of primary glaucoma (POAG and
PACG) and PEX in a Saudi population. Further studies are warranted to understand the role
of APOE allelic isoforms in various ethnic populations and to predict the predisposition to
degenerative eye diseases like PEX and glaucoma.
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